Sign inJoin waitlistJoin the waitlist

Kelly Faulk

Promotion to Associate Professor · University of Colorado School of Medicine

Credentials: · · · · ·

History

University of Colorado School of Medicine
Present

Pediatric Hematology-Oncology
University of Colorado School of Medicine
2015–2016
Pediatrics
University of Colorado School of Medicine
2012–2015
University of Colorado School of Medicine
2008–2012

Research

Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015
PLoS ONE · 2020 · First of 4 authors · Corresponding · 47 citations
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
Leukemia · 2023 · 34 citations
Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia
Review · Paediatric drugs · 2014 · First of 3 authors · 16 citations

EG
Erin Guest
4 papers
Mignon Loh
3 papers
Elizabeth Raetz
2 papers
Erin Breese
2 papers
Lia Gore
2 papers
LM
Lindsey Murphy
2 papers
Stephen Hunger
2 papers
Adam Green
1 paper
Alyssa Reddy
1 paper
AL
Amanda Li
1 paper
Ammar Hayani
1 paper
Ana Aguilar-Bonilla
1 paper

Clinical trials

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Principal investigator · Active not recruiting · Phase 2
Children's Oncology Group
2024–2027
Losartan + Sunitinib in Treatment of Osteosarcoma
Principal investigator · Recruiting · Phase 1
University of Colorado, Denver
2019–2029
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1
St. Jude Children's Research Hospital
2024–2027